Apeloa Pharmaceutical Co Ltd (000739) — Cash Flow Quality Index
Apeloa Pharmaceutical Co Ltd (000739) has a Cash Flow Quality Index of 2.34x as of December 2025. Operating cash flow of CN¥446.18 Million exceeds net income of CN¥190.41 Million, indicating high earnings quality where cash backs reported profits. Explore 000739 operating cash flow to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Apeloa Pharmaceutical Co Ltd Cash Flow Quality Index (1998–2025)
Historical Cash Flow Quality Index for Apeloa Pharmaceutical Co Ltd across 27 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 000739 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Apeloa Pharmaceutical Co Ltd (1998–2025)
Year-by-year earnings quality comparison for Apeloa Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see market value of Apeloa Pharmaceutical Co Ltd.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.38x | CN¥1.23 Billion | CN¥890.68 Million | ▲ +17.8% |
| 2024 | 1.17x | CN¥1.21 Billion | CN¥1.03 Billion | ▲ +20.0% |
| 2023 | 0.98x | CN¥1.03 Billion | CN¥1.06 Billion | ▼ -27.1% |
| 2022 | 1.34x | CN¥1.33 Billion | CN¥989.17 Million | ▲ +109.4% |
| 2021 | 0.64x | CN¥611.75 Million | CN¥955.55 Million | ▼ -50.7% |
| 2020 | 1.30x | CN¥1.06 Billion | CN¥816.73 Million | ▼ -47.2% |
| 2019 | 2.46x | CN¥1.36 Billion | CN¥553.40 Million | ▲ +9.4% |
| 2018 | 2.25x | CN¥832.69 Million | CN¥370.57 Million | ▲ +174.8% |
| 2017 | 0.82x | CN¥209.80 Million | CN¥256.59 Million | ▲ +19.1% |
| 2016 | 0.69x | CN¥180.42 Million | CN¥262.90 Million | ▼ -67.6% |
| 2015 | 2.12x | CN¥441.16 Million | CN¥208.23 Million | ▼ -12.0% |
| 2014 | 2.41x | CN¥786.64 Million | CN¥326.72 Million | ▲ +103.5% |
| 2013 | 1.18x | CN¥190.45 Million | CN¥160.99 Million | ▼ -52.6% |
| 2012 | 2.50x | CN¥335.90 Million | CN¥134.55 Million | ▼ -98.0% |
| 2011 | 125.26x | CN¥404.62 Million | CN¥3.23 Million | ▲ +1970.9% |
| 2010 | 6.05x | CN¥121.05 Million | CN¥20.01 Million | ▼ -4.6% |
| 2009 | 6.34x | CN¥208.30 Million | CN¥32.86 Million | ▲ +74.3% |
| 2008 | 3.64x | CN¥94.57 Million | CN¥26.00 Million | ▼ -41.9% |
| 2007 | 6.26x | CN¥174.20 Million | CN¥27.82 Million | ▲ +100.8% |
| 2006 | 3.12x | CN¥159.43 Million | CN¥51.13 Million | ▲ +64.5% |
| 2005 | 1.90x | CN¥87.40 Million | CN¥46.10 Million | ▲ +49.6% |
| 2004 | 1.27x | CN¥47.54 Million | CN¥37.52 Million | ▼ -55.9% |
| 2003 | 2.87x | CN¥105.36 Million | CN¥36.69 Million | ▲ +3367.7% |
| 2002 | 0.08x | CN¥2.81 Million | CN¥33.98 Million | ▼ -91.2% |
| 2000 | 0.94x | CN¥7.08 Million | CN¥7.52 Million | ▲ +135.0% |
| 1999 | -2.69x | CN¥-20.52 Million | CN¥7.63 Million | ▼ -330.0% |
| 1998 | 1.17x | CN¥30.10 Million | CN¥25.73 Million | — |